Author:
Rosner Samuel,Levy Benjamin
Subject
Pulmonary and Respiratory Medicine
Reference12 articles.
1. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133);Liu;J Clin Oncol,2021
2. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial;Goldman;Lancet Oncol,2021
3. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial;Trigo;Lancet Oncol,2020
4. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial;Ponce Aix;Lancet Respir Med,2022
5. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity;Xie;OncoImmunology,2019